Soligenix (SNGX) PT Set at $4.00 by Maxim Group
Maxim Group set a $4.00 target price on Soligenix (NASDAQ:SNGX) in a research report report published on Thursday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Separately, ValuEngine upgraded Soligenix from a hold rating to a buy rating in a research note on Thursday, November 1st.
NASDAQ SNGX traded up $0.01 during trading on Thursday, hitting $0.98. The stock had a trading volume of 29,181 shares, compared to its average volume of 61,022. Soligenix has a 12 month low of $0.91 and a 12 month high of $3.70.
In other news, Director Mark E. Pearson bought 170,000 shares of the business’s stock in a transaction on Wednesday, October 17th. The shares were purchased at an average price of $1.16 per share, for a total transaction of $197,200.00. Following the purchase, the director now owns 2,500,000 shares of the company’s stock, valued at approximately $2,900,000. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 5.03% of the company’s stock.
Several large investors have recently bought and sold shares of SNGX. Virtu Financial LLC acquired a new position in shares of Soligenix during the 3rd quarter worth approximately $116,000. Renaissance Technologies LLC acquired a new position in shares of Soligenix during the 3rd quarter worth approximately $188,000. Finally, Vanguard Group Inc. increased its position in shares of Soligenix by 46.5% during the 3rd quarter. Vanguard Group Inc. now owns 339,732 shares of the biopharmaceutical company’s stock worth $639,000 after purchasing an additional 107,875 shares during the last quarter. 9.13% of the stock is currently owned by hedge funds and other institutional investors.
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer.
Featured Story: Stock Split
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.